ReviewExpert review of pharmacoeconomics & outcomes research2019
Cost burden of diffuse large B-cell lymphoma.
Review in Expert review of pharmacoeconomics & outcomes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Socioeconomic Status and Access to Treatment in Diffuse Large B-Cell Lymphoma.Cancer medicine · 2026Article
- Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Population based registry study on large B-cell lymphoma mortality and morbidity in Finland.Acta oncologica (Stockholm, Sweden) · 2025Article
- Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts.Frontiers in immunology · 2025Article
- Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China.Frontiers in pharmacology · 2024Article
- Overexpression ofOncoTargets and therapy · 2022Article
- Review
- How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?Leukemia & lymphoma · 2020Article
- Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?International journal of particle therapy · 2020Review
- Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.